Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action
about
Research advances at the Institute for Nutritional Sciences at Shanghai, ChinaArtemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?Development of resistance towards artesunate in MDA-MB-231 human breast cancer cellsAnti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathwayPraziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growthTh1-biased immunomodulation and therapeutic potential of Artemisia annua in murine visceral leishmaniasisCharacterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line.Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51.The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells.The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells.Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo.Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis.Dihydroarteminsin-induced apoptosis is not dependent on the translocation of Bim to the endoplasmic reticulum in human lung adenocarcinoma cells.Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling.Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5Development of artemisinin compounds for cancer treatment.Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1.Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate.Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin.Ionizing radiation potentiates dihydroartemisinin-induced apoptosis of A549 cells via a caspase-8-dependent pathway.Artemether combined with shRNA interference of vascular cell adhesion molecule-1 significantly inhibited the malignant biological behavior of human glioma cells.Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species productionArtemisinin induces A549 cell apoptosis dominantly via a reactive oxygen species-mediated amplification activation loop among caspase-9, -8 and -3.Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine.Anti-cancer natural products isolated from chinese medicinal herbsArtesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model.Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drugDihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells.Artesunate altered cellular mechanical properties leading to deregulation of cell proliferation and migration in esophageal squamous cell carcinoma.Correlation between Cyclin Dependent Kinases and Artemisinin-Induced Dormancy in Plasmodium falciparum In Vitro.Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells.Examination of the cytotoxic and embryotoxic potential and underlying mechanisms of next-generation synthetic trioxolane and tetraoxane antimalarialsDihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts.Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs.Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study.Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones.Ligand-based targeted therapy for cancer tissue.Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer
P2860
Q27000047-C8C3A4A0-3A1B-442F-8BF1-8C8FEB9C64BCQ28066236-A057D7BF-DB50-4A10-928A-3D61DFDF2382Q28478307-67EE60FE-F977-473A-A0BF-7B21BF5D7755Q28478508-809C9B64-EC87-4147-8F8A-CF178E5C5D4FQ28484303-638E0463-D108-4334-A5F4-BAAFFDB1294BQ28542988-79F84BF1-B9D9-41F5-A04E-C2161FE8C079Q31031641-94A63776-0990-41BC-9003-D5716053B8ACQ33564205-D7B35EC7-90ED-4E0B-9CDC-EBD0AB40CA9CQ33626573-F2426B5F-E710-4D16-9100-5E8726909735Q33657899-8A9E35C7-4DC4-4581-B235-EE8FE0022D89Q33666019-95F2D3D6-17B4-43D1-A98E-465B8B886899Q34044000-8892E711-D05E-473B-84E0-2A79EB8C0301Q34185251-E496E5DA-BC0B-4863-8D52-67459C7F6C50Q34231069-48B02C60-D1E9-4CE4-A63A-31167D865BEBQ34292461-96F34743-6687-4F07-91A5-FE8BDC629A0CQ34296810-3B76CCAA-B155-4DE3-A77D-E9412724A05BQ34382566-F23FCA49-8948-4FB4-A4EB-C9CAB7011701Q34532926-C4F6CECB-AEAA-4706-88FE-D8EB2F16A7FAQ34580333-19F730A0-E2C3-4276-8B31-097CC2A978AAQ34639813-A2083513-83AC-41EB-8355-835558AFE70DQ34674201-71421320-D092-48D3-8703-65DB45E9C4ECQ34675798-443E3C36-0028-402E-8EBA-DA1BB49E1DBBQ34714061-5E6E2E84-E31E-4F74-9CD8-1324157D7ED5Q35066769-1B2B67DC-EAC0-4298-A775-EA0F126F5FA1Q35143916-74589180-33B7-4087-A923-D04E914E2806Q35551934-D08379A5-F6F4-4F20-8583-D575E0868801Q35585226-06AB6715-26D2-481B-9ED5-60715F46401DQ35620926-461299F6-35E5-4769-9182-53574230E456Q35742191-3659FF56-DF86-4975-9060-ADDBD481A8C2Q36057571-054E653D-CBF1-4B86-AFD9-4FF8529A8540Q36275798-67E6B456-6FCB-44A2-8283-0870AE43DEC0Q36297935-6F832896-78B4-40D0-A7E3-B5FE761776E7Q36327396-191DD9AC-0AB2-4518-85C7-65DBA3F6D973Q36442668-CD43539D-46ED-451A-8694-34C4AA5EA171Q36545062-D63C4AAB-1422-498E-9B7A-8BDAF53CF882Q36916456-ECC5773E-9215-412B-9F68-A7E9A7AC7D17Q36938452-F53143C4-9C8B-4378-B653-BAA89D26A0BDQ37235359-30D154A2-89EB-407E-A7FB-1D3E3E5CE8F8Q37425224-A4F30B6E-BAFA-4866-92E6-2F072204F10DQ37510221-9CD58C6A-69EE-4B5B-B727-92C6CB0C27D7
P2860
Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@ast
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@en
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@en-gb
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@nl
type
label
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@ast
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@en
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@en-gb
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@nl
altLabel
Experimental therapy of hepato ...... tion, and mechanisms of action
@en
prefLabel
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@ast
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@en
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@en-gb
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@nl
P2093
P3181
P1476
Experimental Therapy of Hepato ...... tion, and Mechanisms of Action
@en
P2093
P304
P3181
P356
10.1158/1078-0432.CCR-08-0197
P407
P577
2008-09-01T00:00:00Z